Fungal Endocarditis Market Information: By Type of Fungus (Candida, Aspergillus), Diagnosis (Blood Test, X-Ray, Echocardiography, Electrocardiogram), Treatment (Antifungal Medication, Surgery, Combined Treatment), End User - Global Forecast till 2023
ID: MRFR/LS/3679-HCR | | Region: Global | 85 pages
Market Scenario
Fungal endocarditis is a rare and extremely enfeebling disease associated with high rate of mortality of around 50%. The condition is usually being diagnosed postmortem. The etiologic fungi more commonly observed are the Candida and Aspergillus species.
As per the study published in the International Cardiovascular Research Journal in 2014, it is found that Candida albicans, and Aspergillus species are the most frequent cause of fungal endocarditis. Candida albicans is found to be responsible for 24%-46% of cases of fungal endocarditis, and for 3.4% of the prosthetic valve endocarditis cases with associated mortality rates of 46.6%-50%. After Candida, Aspergillus species is the second most common cause of fungal endocarditis, accounting for nearly 25% of the cases of fungal endocarditis in cardiac valve prostheses and the great vessels.
With an increasing age, the incidence of Candida fungal endocarditis decreases whereas the incidence of Aspergillus fungal endocarditis increases. The affected cardiac sites in neonates is significantly different from the adults with the right atrium being predominant in 63% of neonates
The possible complications associated with fungal endocarditis are congestive heart failure, mitral and aortic valve incompetence, neurological complications, formation of myocardial abscesses, and metastatic infections. According to a study published in PLOS one in 2013, it is found that the incidence of hospitalization for fungal endocarditis in the United States is 12.7 per 100,000 annually.
Notably, rising awareness about fungal infections is the key factor driving the fungal endocarditis market. Nowadays, people are becoming more aware about the different types of fungal infections. Government and other different organizations have started educating people about the hygiene and infectious diseases. People are becoming more aware and conscious about the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other push factors such as increasing incidents of fungal infections, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global fungal endocarditis market.
Despite these drivers, there are some issues associated with fungal endocarditis market. Some of the challenges in research and development are side-effects of treatment, presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, which may hinder the growth of the market to an extent. In contrast to the remedial effects, antifungal treatment can have many side effects as well. Some of them include: irritation, itching, headache, diarrhoea, and anaemia. They are also responsible for causing kidney and liver damage. Beside this, many antifungal medicines can cause allergic reactions, thus, they are not prescribed to pregnant women and children.
It is estimated that the fungal endocarditis market is expected to grow at a CAGR 4.2% during the forecast period of 2017-2023.
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Segmentation
The global fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.
On the basis of the type of causative agent, the market is segmented into Candida species
Aspergillus species, and Histoplasma capsulatum.
On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram
On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.
On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
The Asia Pacific is the fastest growing fungal endocarditis market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the global fungal endocarditis market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, and Others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Frequently Asked Questions (FAQ) :
The global fungal endocarditis market can expand at 4.2% CAGR from 2017 to 2023.
Massive number of cases of Candida fungal endocarditis is the major driver of the global fungal endocarditis market.
The Americas can dominate the global fungal endocarditis market due to increasing awareness among the populace.
Europe is the second largest region in the global fungal endocarditis market.
Sanofi, Enzon Pharmaceuticals, Inc., Merck & Co., Sigma-Aldrich, Eli Lily and Company, Pfizer, GlaxoSmithKline plc, Abbott Laboratories, Bayer AG, Astellas Pharma, Inc., and Novartis AG are notable players of the global fungal endocarditis market.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Fungal Endocarditis Market, by Type of Causative Agent
6.1 Introduction
6.2 Candida species
6.2.1 Market Estimates & Forecast, 2017 – 2023
6.3 Aspergillus species
6.3.1 Market Estimates & Forecast, 2017 – 2023
6.4 Histoplasma capsulatum
6.4.1 Market Estimates & Forecast, 2017 – 2023
Chapter 7. Global Fungal Endocarditis Market, by Diagnosis
7.1 Introduction
7.2 Physical Examination
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Blood Test
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 X-ray
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Echocardiography
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Electrocardiogram
7.6.1 Market Estimates & Forecast, 2017 – 2023
Chapter 8. Global Fungal Endocarditis Market, by treatment
8.1 Introduction
8.2 Antifungal Medication
8.2.1 Market Estimates & Forecast, 2018 – 2023
8.3 Surgery
8.3.1 Market Estimates & Forecast, 2018 – 2023
8.4 Combined Treatment
8.4.1 Market Estimates & Forecast, 2018 – 2023
Chapter 9. Global Fungal Endocarditis Market, by End User
9.1 Introduction
9.2 Hospital
9.2.1 Market Estimates & Forecast, 2017 – 2023
9.3 Clinics
9.3.2 Market Estimates & Forecast, 2017 – 2023
9.4 Diagnostic Centers
9.4.1 Market Estimates & Forecast, 2017 – 2023
9.5 Others
9.5.2 Market Estimates & Forecast, 2017 – 2023
Chapter 10. Global Fungal Endocarditis Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Pfizer
12.1.1 Company Overview
12.1.2 Type of Causative Agents Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Merck & Co.
12.2.1 Company Overview
12.2.2 Type of Causative Agents Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Sanofi
12.3.1 Company Overview
12.3.2 Type of Causative Agents Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Astellas Pharma, Inc.
12.4.1 Company Overview
12.4.2 Type of Causative Agents/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 GlaxoSmithKline plc
12.5.1 Company Overview
12.5.2 Type of Causative Agents Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Novartis AG
12.6.1 Company Overview
12.6.2 Type of Causative Agents Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 ENZON PHARMACEUTICALS
12.7.1 Overview
12.7.2 Type of Causative Agents Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Fungal Endocarditis industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Fungal Endocarditis Industry Synopsis, 2017 – 2023
Table 2 Fungal Endocarditis Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Fungal Endocarditis Market by Region, 2017 – 2023, (USD Million)
Table 4 Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 5 Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 6 Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 7 Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 9 North America Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 10 North America Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 11 North America Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 12 US Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 13 US Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 US Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 15 US Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 16 Canada Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 17 Canada Fungal Endocarditis market by Diagnosis, 2017 – 2023, (USD Million)
Table 18 Canada Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 19 Canada Fungal Endocarditis market by End Users, 2017 – 2023, (USD Million)
Table 20 South America Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 21 South America Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 23 South America Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 24 Europe Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 25 Europe Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Europe Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Europe Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 28 Western Europe Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 29 Western Europe Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 30 Western Europe Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 31 Western Europe Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Fungal Endocarditis market by Diagnosis, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Fungal Endocarditis Market by End Users, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Fungal Endocarditis market by End Users, 2017 – 2023, (USD Million)
Table 40 Middle East & Africa Fungal Endocarditis Market by Type of Causative Agent, 2017 – 2023, (USD Million)
Table 41 Middle East & Africa Fungal Endocarditis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 42 Middle East & Africa Fungal Endocarditis Market by Treatment, 2017 – 2023, (USD Million)
Table 43 Middle East & Africa Fungal Endocarditis market by End Users, 2017 – 2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Fungal Endocarditis Market
Figure 3 Segmentation Market Dynamics for Fungal Endocarditis Market
Figure 4 Global Fungal Endocarditis market Share, by Type of Causative Agent 2016
Figure 5 Global Fungal Endocarditis market Share, by Diagnosis 2016
Figure 6 Global Fungal Endocarditis market Share, by Treatment 2016
Figure 7 Global Fungal Endocarditis market Share, by End Users, 2016
Figure 8 Global Fungal Endocarditis market Share, by Region, 2016
Figure 9 North America Fungal Endocarditis market Share, by Country, 2016
Figure 10 Europe Fungal Endocarditis market Share, by Country, 2016
Figure 11 Asia Pacific Fungal Endocarditis market Share, by Country, 2016
Figure 12 Middle East & Africa Fungal Endocarditis market Share, by Country, 2016
Figure 13 Global Fungal Endocarditis market: Company Share Analysis, 2016 (%)
Figure 14 Pfizer: Key Financials
Figure 15 Pfizer Segmental Revenue
Figure 16 Pfizer: Geographical Revenue
Figure 17 Merck & Co.: Key Financials
Figure 18 Merck & Co.: Segmental Revenue
Figure 19 Merck & Co.: Geographical Revenue
Figure 20 Sanofi: Key Financials
Figure 21 Sanofi: Segmental Revenue
Figure 22 Sanofi: Geographical Revenue
Figure 23 Astellas Pharma, Inc.: Key Financials
Figure 24 Astellas Pharma, Inc.: Segmental Revenue
Figure 25 Astellas Pharma, Inc.: Geographical Revenue
Figure 26 GlaxoSmithKline plc: Key Financials
Figure 27 GlaxoSmithKline plc: Segmental Revenue
Figure 28 GlaxoSmithKline plc Geographical Revenue
Figure 29 Novartis AG: Key Financials
Figure 30 Novartis AG: Segmental Revenue
Figure 31 Novartis AG: Geographical Revenue
Figure 32 ENZON PHARMACEUTICALS: Key Financials
Figure 33 ENZON PHARMACEUTICALS: Segmental Revenue
Figure 34 ENZON PHARMACEUTICALS: Geographical Revenue
